SGN-35

Description

SGN-35 is an antibody-drug conjugate (ADC) consisting of an anti-CD30 monoclonal antibody attached by a proprietary, enzyme-cleavable linker to a derivative of the highly potent class of cell-killing drugs called Auristatins. The ADC binds to receptors on target cells, undergoes rapid internalization and then releases active drug from the antibody carrier inside the cell. The linkage system is highly stable in plasma. Thus, SGN-35 is designed to have low toxicity and high specificity for antigen positive target cells.

Development Status

SGN-35 is in phase I clinical trials for patients with relapsed Hodgkin lymphoma or other CD30-positive hematologic malignancies. Multiple objective responses have been observed at well-tolerated doses.

SGN-35 has orphan drug designation from the FDA for Hodgkin lymphoma.